Medicinal products containing flupirtine: Risk of liver toxicity
2013.07.16
Active substance: flupirtine
The marketing authorisation holders of medicinal products containing flupirtine are sending out information that a restriction of the therapeutic target group and a limitation of the duration of treatment have become necessary for medicinal products containing flupirtine after evaluation of the hepatotoxic risk.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN